Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
Yan Zhang(Jiangsu Cancer Hospital), Bo Shen(Jiangsu Cancer Hospital), Guohong Ling, Shaodi Wen(Jiangsu Cancer Hospital), Zhengxiang Han(Xuzhou Medical College), Jingfeng Mei(Jiangsu Cancer Hospital), Yang Yang(Shijiazhuang Yiling Pharmaceutical (China)), Qiong Wang(Jiangnan University), Lin Shi(Qingdao University), Jifeng Feng(Zhejiang Cancer Hospital), Yuan Wu(Jiangsu Cancer Hospital), Yong Mao(Jiangnan University), Maohuai Cai(Yancheng Second People's Hospital), Junying Xu(Wuxi People's Hospital)
Cited by 10
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Comprehensive molecular characterization of mitochondrial genomes in human cancers
|Nature Genetics|2020|520